Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents

被引:94
作者
Choi, Chang-Ik [1 ]
机构
[1] Dongguk Univ Seoul, Coll Pharm, Goyang 10326, South Korea
关键词
type 2 diabetes mellitus; sodium-glucose cotransporter; SGLT2; inhibitor; natural product; phlorizin; TYPE-2; DIABETES-MELLITUS; INADEQUATE GLYCEMIC CONTROL; DAILY REMOGLIFLOZIN ETABONATE; PLACEBO-CONTROLLED TRIAL; PROXIMAL TUBULAR CELLS; DOUBLE-BLIND; SERGLIFLOZIN ETABONATE; SELECTIVE INHIBITOR; NA+/GLUCOSE COTRANSPORTER; DOSE PHARMACOKINETICS;
D O I
10.3390/molecules21091136
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetes mellitus is a chronic condition associated with the metabolic impairment of insulin actions, leading to the development of life-threatening complications. Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, weight gain, and hepato-renal toxicity, have increased demand for the discovery of novel, safer antidiabetic drugs. Since the important roles of the sodium-glucose cotransporter 2 (SGLT2) for glucose homeostasis in the kidney were recently elucidated, pharmacological inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes. Since the discovery of the first natural SGLT2 inhibitor, phlorizin, several synthetic glucoside analogs have been developed and introduced into the market. Furthermore, many efforts to find new active constituents with SGLT2 inhibition from natural products are still ongoing. This review introduces the history of research on the development of early-generation SGLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine.
引用
收藏
页数:12
相关论文
共 73 条
[51]   Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia [J].
Rieg, Timo ;
Masuda, Takahiro ;
Gerasimova, Maria ;
Mayoux, Eric ;
Platt, Kenneth ;
Powell, David R. ;
Thomson, Scott C. ;
Koepsell, Hermann ;
Vallon, Volker .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 306 (02) :F188-F193
[52]   Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy [J].
Rosenstock, Julio ;
Vico, Marisa ;
Wei, Li ;
Salsali, Afshin ;
List, James F. .
DIABETES CARE, 2012, 35 (07) :1473-1478
[53]   Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes [J].
Rosenstock, Julio ;
Aggarwal, Naresh ;
Polidori, David ;
Zhao, Yue ;
Arbit, Deborah ;
Usiskin, Keith ;
Capuano, George ;
Canovatchel, William .
DIABETES CARE, 2012, 35 (06) :1232-1238
[54]   CORRECTION OF HYPERGLYCEMIA WITH PHLORIZIN NORMALIZES TISSUE SENSITIVITY TO INSULIN IN DIABETIC RATS [J].
ROSSETTI, L ;
SMITH, D ;
SHULMAN, GI ;
PAPACHRISTOU, D ;
DEFRONZO, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (05) :1510-1515
[55]   Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flaveseens [J].
Sato, Seizo ;
Takeo, Jiro ;
Aoyama, Chihiro ;
Kawahara, Hiroyuki .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (10) :3445-3449
[56]   The renal tubular reabsorption of glucose in the normal dog [J].
Shannon, JA ;
Fisher, S .
AMERICAN JOURNAL OF PHYSIOLOGY, 1938, 122 (03) :765-774
[57]   Gneyulins A and B, Stilbene Trimers, and Noidesols A and B, Dihydrofluvonol-C-Glucosides, from the Bark of Gnetum gnemonoides [J].
Shimokawa, Yoko ;
Akao, Yusuke ;
Hirasawa, Yusuke ;
Awang, Khalijah ;
Hadi, A. Hamid A. ;
Sato, Seizo ;
Aoyama, Chihiro ;
Takeo, Jiro ;
Shiro, Motoo ;
Morita, Hiroshi .
JOURNAL OF NATURAL PRODUCTS, 2010, 73 (04) :763-767
[58]   Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise [J].
Stenlof, K. ;
Cefalu, W. T. ;
Kim, K. -A. ;
Alba, M. ;
Usiskin, K. ;
Tong, C. ;
Canovatchel, W. ;
Meininger, G. .
DIABETES OBESITY & METABOLISM, 2013, 15 (04) :372-382
[59]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial [J].
Strojek, K. ;
Yoon, K. H. ;
Hruba, V. ;
Elze, M. ;
Langkilde, A. M. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2011, 13 (10) :928-938
[60]   Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes [J].
Sykes, A. P. ;
O'Connor-Semmes, R. ;
Dobbins, R. ;
Dorey, D. J. ;
Lorimer, J. D. ;
Walker, S. ;
Wilkison, W. O. ;
Kler, L. .
DIABETES OBESITY & METABOLISM, 2015, 17 (01) :94-97